Benzinga | Aug 12, 2021 06:37AM EDT

Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study

* After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ:APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study.

* The trial is evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.

* The agency's concerns referred to the safety and efficacy data from the Phase 3 myelodysplastic syndromes (MDS) clinical trial.

* One chronic lymphocytic leukemia (CLL) patient is currently on study treatment receiving eprenetapopt / venetoclax / rituximab combo and has achieved complete remission (CR).

* No additional patients can be enrolled until the clinical hold is resolved.

* Price Action: APRE shares are down 12.20% at $3.60 during the premarket session on the last check Thursday.

* Related content: Benzinga's Full FDA Calendar